What is ANIK's market cap?

$271.94M, based on the Nov 4 close of $20.32.

Does Anika Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ANIK is sold short?

365.7K shares, 3.2% of float, as of Oct 15, 2026.

What sector is ANIK in?

Healthcare, in the Surgical Instruments industry.

NASDAQ · ANIKHealthcareSurgical Instruments

Anika Therapeutics Inc (ANIK)

$20.32+4.47%

Close Nov 4, 2026 · split-adjusted

Nov 2, 2026$19.41▲ 97.66% in range

Nov 3, 2025Low $9.13 · High $22.03Nov 2, 2026

What changed · written from our data

As of Nov 4, 2026

Anika Therapeutics closed at $20.32 on Nov 4, up 4.47%, 7.8% below its 52-week closing high. Volume of 51.4K shares was 0.48× its 20-day average (below normal).

Split-adjusted performance: +6.3% over one month, +34.4% over six months, +106.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $32.61M, up 15.6% from a year earlier, with a net margin of 10.1%.

Short interest was 365.7K shares at the Oct 15 settlement (3.2% of float, 3.4 days to cover).

Market cap$271.9M13.4M shares

Revenue · quarter$32.6M+15.6% YoY

Diluted EPS$0.24—

P/E · TTM—P/S 2.3×

Net margin10.1%Gross 65.1%

Dividend yieldNone

52-week range9.13 – 22.03−7.8% from high

Volume51.4K0.48× 20-day avg

Volatility · 60d34.9%Annualised

Short % of float3.2%3.4 days to cover

Net cash$38.4MCash $38.4M

Next earnings—Not scheduled

Split-adjusted performance

1W −5.7%1M +6.3%3M +0.8%6M +34.4%YTD +111.4%1Y +106.9%3Y +7.0%5Y −50.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum75

Revenue growth63

Net margin78

Value (low P/E)—

Size49

Industry medians: 6-month return −4.4%, revenue growth +8.9%, net margin −8.2%, P/E 29.7×.

Short interest

Details →

Shares short365.7K−0.4% vs prior

Days to cover3.4Settled Oct 15

% of float3.2%

Short vol. 10d47.0%of daily volume

Closest peers by size in Surgical Instruments

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ANIKAnika Therapeutics	$20.32	+4.47%	+34.4%	+15.6%	10.1%	—	$271.9M
PROFProfound Medical	$7.13	+2.00%	−1.2%	+12.3%	−384.2%	—	$260.5M	Compare
INFUInfuSystem Holdings	$13.04	+1.84%	+28.6%	+2.6%	8.7%	30.4	$259.6M	Compare
OSUROraSure Technologies	$3.66	+3.68%	+22.0%	−1.9%	20.4%	—	$252.4M	Compare
TMCITreace Medical Concepts	$4.58	+6.89%	+137.0%	−4.2%	−35.0%	—	$297.5M	Compare
TLSITriSalus Life Sciences	$3.99	+14.66%	−12.3%	+1.7%	−80.5%	—	$245.7M	Compare
UTMDUtah Medical Products	$71.74	+2.46%	+11.4%	−14.3%	31.5%	21.7	$227.8M	Compare
CLPTClearPoint Neuro	$10.30	+6.08%	−10.2%	+36.3%	−61.8%	—	$330.2M	Compare
STIMNeuronetics	$2.82	+24.56%	+47.4%	+9.1%	−8.3%	—	$214.5M	Compare

News about Anika Therapeutics

All news →

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Jun 5, 2026Neutral

Quick answers

What does Anika Therapeutics do?: Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services.
What is ANIK's market cap?: $271.94M, based on the Nov 4 close of $20.32.
Does Anika Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ANIK is sold short?: 365.7K shares, 3.2% of float, as of Oct 15, 2026.
What sector is ANIK in?: Healthcare, in the Surgical Instruments industry.

About Anika Therapeutics

Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

HQ: Bedford, MA235 employeesListed May 3, 1993anika.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology